Figure 4. mCD13‐AFR synergizes with immunotherapy.

• A
  Schematic representation of the CAR construct used, consisting of N‐terminal anti‐hCD70 VHH, hCD8α hinge and transmembrane (TM) domain, CD137 co‐stimulatory domain, and C‐terminal CD3ζ activation domain.
• B, C
  SKOV3 tumor growth in NSG mice after i.v. injection of 6 × 10⁶ hCD70 CAR T cells on day 12 and p.l. treatment with 50 μg mCD13‐AFR (↑). Tumor growth is shown as mean TSI, and error bars are SEM (n = 5) (B) or as TSI of individual mice (C). ***P < 0.001 by two‐way ANOVA with Bonferroni's multiple comparison test.
• D
  Flow cytometric analysis of hCD45⁺hCD3⁺eGFP⁺ CAR T cells in SKOV3 tumors on day 18 after tumor inoculation. Mice were injected with 6 × 10⁶ CAR T cells on day 12 and treated with PBS or CD13‐AFR (↑ in panel B). Two replicate tumors are shown. See Figure EV1A for gating strategy.
• E
  B16Bl6 tumor growth and body weight change after daily p.l. injection of 30 μg mCD8‐AFN, 50 μg mCD13‐AFR, or a combination thereof. Tumor growth is shown as mean TSI + SEM (n = 6). The line under the graph represents the treatment period.
• F
  TSI of individual tumors of the indicated treatment groups at day 19 after tumor inoculation. Error bars are SEM. ***P < 0.001 by one‐way ANOVA with Bonferroni's multiple comparison test.

Source data are available online for this figure.